India's fertility services sector has seen remarkable expansion since the arrival of IVF in the 1990s. Initially fueled by local needs, the industry now fulfills two roles addressing the challenges faced by Indian couples with infertility and appealing to overseas patients looking for economical and high-standard reproductive services. Fertility tourism is particularly significant in urban areas like Mumbai, Delhi, and Chennai, where clinics provide treatment and travel packages at significantly lower prices than those in Western countries. Anand in Gujarat became a surrogacy center in the early 2000s, with Dr. Nayna Patel's Akanksha Infertility Clinic at the forefront of commercial surrogacy, gaining recognition through key cases and extensive media coverage. Despite the ban on commercial surrogacy in India in 2021, Anand’s historical significance remains integral to the story of fertility advancements in the country.

From a technical perspective, India presents a complete range of assisted reproductive technologies (ART). In vitro fertilization (IVF) is the process of fertilizing eggs using sperm outside the woman's body and then placing the embryos into the uterus. Intracytoplasmic sperm injection (ICSI) is a specific type of IVF in which a single sperm is injected straight into an egg, making it suitable for male infertility issues. Intrauterine insemination (IUI) is a less intrusive method that involves directly inserting processed sperm into the uterus during ovulation, commonly utilized as a first approach for minor infertility challenges. India’s research and development scene aims to make access more equitable through innovations such as tele-fertility services and cost-effective IVF methods. The advancement of miniaturized lab-on-chip technology for semen and embryo evaluation, AI-driven embryo assessment, and mobile teleconsultation formats is underway to extend services to smaller cities and rural locations.

This combination of cost-efficiency, modernity, and accessibility is establishing India as an emerging frontrunner in fertility healthcare.According to the research report, "India Fertility Service Market Research Report, 2030," published by Actual Market Research, the India Fertility Service market is anticipated to grow at 11.94% CAGR from 2025 to 2030. This growth is fueled by increasing infertility rates, delayed family planning, and a heightened awareness of assisted reproductive technologies (ART). The regulatory environment for the industry was significantly changed with the introduction of the Assisted Reproductive Technology (Regulation) Act, 2021, which requires ART clinics and banks to register, adhere to ethical standards, and follow established protocols. Alongside the Surrogacy (Regulation) Act, 2021, this framework disallows commercial surrogacy, sets donor eligibility requirements, and guarantees informed consent, insurance, and traceability for gametes and embryos. Prominent companies such as Nova IVF, Indira IVF, and Cloudnine Fertility are major players in urban fertility services. Nova IVF operates more than 99 centers in 63 cities, focusing on self-cycle IVF and clear pricing. Indira IVF has over 165 centers nationwide, providing advanced services such as ICSI, PGT, and donor programs.

Cloudnine Fertility utilizes advanced technologies like time-lapse embryo monitoring and laser-assisted hatching, prioritizing comprehensive care and strong infrastructure. The forthcoming growth opportunities are found in tier-2 and tier-3 cities, where there is a rising demand due to lifestyle shifts, increased awareness of infertility, and decreasing stigma. Companies like Birla Fertility and Nova IVF are extending their reach into underrepresented areas such as Haldwani, Siliguri, and Vellore, delivering standardized care and donor services at affordable rates. Programs for donor eggs and sperm are on the rise, though strict adherence to donor age, marital status, and single-use regulations under the ART Act has created some supply challenges. The fertility industry in India is characterized by a combination of ethical oversight, clinical advancements, and geographical growth, positioning it as a vibrant, inclusive, and competitive player on the stage.The landscape of fertility in India by procedure is divided into IVF with ICSI, IUI, IVF without ICSI, Surrogacy and Others is changing swiftly, with the use of in vitro fertilization (IVF) combined with intracytoplasmic sperm injection (ICSI) becoming the most rapidly expanding method, mainly due to the rise in male-factor infertility. Issues such as oligospermia, asthenospermia, and varicocele are being increasingly identified among men in urban areas, leading clinics to implement ICSI as their standard approach for fertilization.

ICSI allows for the direct insertion of sperm into the egg, avoiding complications related to sperm motility and shape, and can now be found in leading facilities like Nova IVF, Indira IVF, and Cloudnine Fertility. Its success rates in situations involving male-factor infertility frequently surpass those of traditional IVF, making it a favored option for couples facing significant sperm issues. Intrauterine insemination (IUI) remains well-liked because of its low cost and straightforwardness. Priced between ₹7,000 and ₹25,000 per cycle based on the area, IUI is often the initial treatment choice for mild infertility, unexplained situations, or for single women and same-sex couples using donor sperm. This procedure entails placing processed sperm directly into the uterus when ovulation occurs, enhancing the likelihood of conception without using invasive techniques. IVF without ICSI is given selectively to younger couples who have healthy sperm parameters and no history of fertilization difficulties.

Although it is less frequently used, it remains a practical choice in low-intervention strategies and budget-conscious environments, particularly in tier-2 cities where knowledge and availability are improving. Surrogacy in India has been strictly regulated following the introduction of the Surrogacy (Regulation) Act, 2021. Only altruistic surrogacy is allowed, with stringent eligibility standards for prospective couples and surrogate mothers. In India fertility service by cause of infertility is divided into Male Infertility and Female Infertility infertility in women is the primary cause of reproductive issues, with disorders such as polycystic ovary syndrome (PCOS) and endometriosis making up a large portion of the cases. PCOS affects approximately one in five women of childbearing age in India, causing ovulation to be interrupted due to hormonal imbalances, resistance to insulin, and high levels of male hormones. Endometriosis, which is thought to influence around 42 million women across the country, is frequently diagnosed late occasionally 7 to 10 years after initial symptoms appear resulting in ongoing pelvic discomfort, inflammation, and difficulties with fertility.

The Indian Council of Medical Research (ICMR) has implemented the EndoCare India model, a comprehensive program merging gynecology, surgical procedures, mental health care, and nutritional support to tackle these issues in a well-rounded manner. These health challenges are worsened by postponed parenthood, stress in urban areas, and limited access to early diagnosis, especially in semi-urban and rural locales. Male infertility, which used to be overlooked, is now surging dramatically because of lifestyle choices and environmental influences. Specialists indicate that male factors are responsible for nearly 40–50% of India’s 27.5 million cases of infertility. Unactive lifestyles, obesity, tobacco use, alcohol consumption, and contact with chemicals that disrupt hormonal function, like BPA and phthalates, are harming sperm quality and hormone systems. Over the last twenty years, sperm count and movement have decreased consistently, with younger males increasingly impacted.

Issues such as erectile dysfunction, hormone imbalances, and undiagnosed sexually transmitted infections (STIs) are common but often remain untreated due to social stigma and a lack of understanding. In Japan fertility service by end user is divided into Fertility Clinics, Hospitals, Surgical Centers and Clinical Research Institutes the provision of fertility care is organized through a well-established framework that combines hospitals, specialized clinics, surgical facilities, and leading research centers, all contributing uniquely to assist couples experiencing infertility. Prominent hospitals incorporate assisted reproductive technologies (ART) within their medical services, providing treatments like in vitro fertilization (IVF), intrauterine insemination (IUI), and fertility preservation, all covered by the national insurance scheme. These hospital services guarantee that ART remains accessible and governed within Japan’s public healthcare system. In terms, private fertility clinics predominantly concentrate on IVF and intracytoplasmic sperm injection (ICSI), offering state-of-the-art laboratory settings, tailored treatment strategies, and advanced methods like preimplantation genetic testing and cryopreservation. Such clinics are often leaders in providing patient-oriented care, drawing in couples who seek specialized knowledge and improved success rates.

Surgical facilities also serve a crucial function by tackling physical reasons for infertility, such as endometriosis, uterine fibroids, and blocked fallopian tubes, using minimally invasive and advanced surgical techniques. By rectifying these underlying issues, these centers enhance the likelihood of natural conception and the success of ART. At the forefront of advancement, research institutes in Japan are pioneering the use of robotics and artificial intelligence (AI) within ART laboratories. Robotics are progressively being utilized to automate intricate tasks, including sperm injection and embryo management, while AI aids in evaluating embryo viability, enabling more accurate selection and improved treatment outcomes. These research initiatives underscore Japan’s dedication to fusing technological progress with medical practice, ensuring that fertility treatments remain effective, safe, and affordable. Considered in this report• Historic Year: 2019• Base year: 2024• Estimated year: 2025• Forecast year: 2030Aspects covered in this report• Fertility Services Market with its value and forecast along with its segments• Various drivers and challenges• On-going trends and developments• Top profiled companies• Strategic recommendationBy Procedure • IVF with ICSI• IUI• IVF without ICSI• Surrogacy• Others By Service • Fresh Non-Donor• Frozen Non-Donor• Egg and Embryo Banking• Fresh Donor• Frozen DonorBy Cause of Infertility • Male Infertility• Female InfertilityBy End User • Fertility Clinics• Hospitals• Surgical Centers• Clinical Research InstitutesConsidered in this report• Historic Year: 2019• Base year: 2024• Estimated year: 2025• Forecast year: 2030Aspects covered in this report• Fertility Services Market with its value and forecast along with its segments• Various drivers and challenges• On-going trends and developments• Top profiled companies• Strategic recommendationBy Procedure • IVF with ICSI• IUI• IVF without ICSI• Surrogacy• Others By Service • Fresh Non-Donor• Frozen Non-Donor• Egg and Embryo Banking• Fresh Donor• Frozen DonorBy Cause of Infertility • Male Infertility• Female InfertilityBy End User • Fertility Clinics• Hospitals• Surgical Centers• Clinical Research Institutes.